Last reviewed · How we verify

Symlin — Competitive Intelligence Brief

Symlin (PRAMLINTIDE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Amylin receptor AMY2, Amylin receptor AMY1, Amylin receptor AMY3 Metabolic Recombinant protein Live · refreshed every 30 min

Target snapshot

Symlin (PRAMLINTIDE) — Astrazeneca Ab.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Symlin TARGET PRAMLINTIDE Astrazeneca Ab marketed Amylin receptor AMY2, Amylin receptor AMY1, Amylin receptor AMY3 2005-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Symlin — Competitive Intelligence Brief. https://druglandscape.com/ci/pramlintide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: